Predict your next investment

Public-Private Partnership
sodena.com

See what CB Insights has to offer

Investments

57

Portfolio Exits

1

About SODENA

Sodena is the financial instrument of the Government of Navarra for the development of business in the region. The firm uses venture capital to make investments and works by taking an active role in the different phases of business projects that contribute to the balanced and sustainable development of Navarra.

SODENA Headquarter Location

Avenida Carlos III el Noble, 36, 1º Dcha

Pamplona, 31003,

Spain

+34 848 421942

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest SODENA News

Ardena acquires Idifarma from Suanfarma and Sodena, adding spray drying technology and high potency capabilities

Sep 28, 2021

Ardena acquires Idifarma from Suanfarma and Sodena, adding spray drying technology and high potency capabilities Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO), has announced that it has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs. The acquisition from Suanfarma delivers expansion across Southern Europe and supports Ardena’s strategy to become a leading global CDMO, offering integrated solutions across the full pharma development lifecycle. Idifarma, based in Pamplona, Spain, offers a full range of services spanning the pharma lifecycle from formulation, analytical to manufacturing services for highly potent drugs. Its capabilities include a platform for an accelerated path to clinic and innovating spray drying processes to overcome solubility issues. Established in 2001, and backed by Sodena, Idifarma now has 120 employees. Harry Christiaens, CEO of Ardena, commented: “At Ardena, our goal is to become a single source contractor offering an integrated set of services to meet chemical, pharmaceutical and bio-analytical needs that arise throughout the clinical supply chain, from lab to patient. This is the main driver of our M&A strategy. We’re delighted to welcome Idifarma who share the science-led approach needed to deliver valuable and integrated solutions for our biopharma customers globally. The combination of Idifarma and Ardena will also create potential to accelerate growth at the Pamplona facility.” Commenting on the acquisition, Francisco Fernandez, CEO of Suanfarma added: “Idifarma has been a successful division within Suanfarma for 5 years. However, Suanfarma’s strategy is increasingly focused on growing our exposure to ingredients for the pharmaceutical and nutraceutical industries. As a result, Idifarma is no longer core to our strategy, and it therefore makes sense for us to dispose of the business to a group capable of maximizing its future potential.” “Joining Ardena enables us to better serve our customers with broader services covering API, Drug Product, regulatory CMC, and bioanalysis requirements. With complementary services and shared experience, we’re delighted to partner with Ardena, to consolidate our leading position in drug development and clinical supply services”, explains Alfredo Gomez, CEO of Idifarma. Harry Christiaens (Ardena) continues: “The Idifarma acquisition expands our pharmaceutical technology footprint, positioning Ardena to capitalise on the emerging biotech segment and broader pharmaceutical market. In partnership with GHO Capital, we will continue to focus on both organic growth and acquisition opportunities to create an internationally recognised drug development company.” The acquisition brings the total number of Ardena facilities in Europe to seven, including its headquarters in Ghent, Belgium, three sites in the Netherlands and two sites in Northern Europe (Sweden and Latvia). ENDS About Ardena Group Ardena is a multi-service CDMO, assisting biopharma companies with services spanning the full development life cycle. The Company offers a comprehensive ‘Make, Analyse, File’ model from drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development. With a strong reputation for quality and a flexible service delivery model, Ardena caters to a highly diversified base of over 300 customers throughout Europe, the US, Japan and Korea. A high science approach and broad drug development toolkit differentiate Ardena from peers as a comprehensive multi-service pan-European platform. For more information, please visit  www.ardena.com . About GHO Capital Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit  www.ghocapital.com/ About Suanfarma/Idifarma/Sodena Suanfarma founded in 1993, is a B2B life science partner specialized in the development, production and commercialization of ingredients for the pharmaceutical, veterinary and nutraceutical industries. With APIs facilities that comply with the highest existing regulations in the pharmaceutical industry and a consolidated and strong commercial network with 12 local offices placed strategically around the world, Suanfarma provides its services to more than 2.000 active customers in over 70 countries, which offers a global vision of the pharmaceutical and nutraceutical market in real time. Idifarma is a leading CDMO invented for potent product R&D and manufacturing that provides services to over 100 international pharmaceutical companies. Combining deep expertise and technological capabilities, Idifarma creates meaningful partnerships built on trust and collaboration to ensure simple, quick and successful delivery of drug development and manufacturing projects. From pre-formulation through to clinic, Idifarma offers tailored services under one roof to develop, scale and manufacture the product across its lifecycle. Sodena, Sociedad de Desarrollo de Navarra, S.L., set up in 1984 as a regional state-owned company, is the instrument of the Government of Navarra to attract and develop value-added business projects for Navarra, supporting them financially, accompanying and facilitating their location and making their network of contacts available to them; as well as to coordinate the design and implementation of the regional Smart Specialization Strategy contributing to regional development and the creation of quality employment. Its current portfolio amounts to more than 140 companies; directly or indirectly participated through seven venture capital funds. Editor Details

SODENA Investments

57 Investments

SODENA has made 57 investments. Their latest investment was in MOA Foodtech as part of their Seed VC on October 10, 2021.

CBI Logo

SODENA Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/18/2021

Seed VC

MOA Foodtech

$1.69M

Yes

1

6/25/2021

Grant

Sonagar

Yes

1

6/25/2021

Grant

Elkargi

$0.15M

Yes

1

4/29/2021

Unattributed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

4/27/2021

Loan

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/18/2021

6/25/2021

6/25/2021

4/29/2021

4/27/2021

Round

Seed VC

Grant

Grant

Unattributed VC - II

Loan

Company

MOA Foodtech

Sonagar

Elkargi

Subscribe to see more

Subscribe to see more

Amount

$1.69M

$0.15M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

SODENA Portfolio Exits

1 Portfolio Exit

SODENA has 1 portfolio exit. Their latest portfolio exit was Vectia on June 09, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/9/2020

Merger

1

Date

6/9/2020

Exit

Merger

Companies

Valuation

Acquirer

Sources

1

SODENA Acquisitions

2 Acquisitions

SODENA acquired 2 companies. Their latest acquisition was Aperitivos Gus on July 30, 2011.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/30/2011

Acq - Fin

1

2/28/2011

Leveraged Buyout

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/30/2011

2/28/2011

Investment Stage

Leveraged Buyout

Companies

Subscribe to see more

Valuation

Total Funding

$99M

Note

Acq - Fin

Subscribe to see more

Sources

1

10

SODENA Team

4 Team Members

SODENA has 4 team members, including current Chief Executive Officer, Jose Maria Aracama Yoldi.

Name

Work History

Title

Status

Jose Maria Aracama Yoldi

Chief Executive Officer

Current

Jose Maria Roig

President

Current

Maria Puy Echarri Ventura

Managing Director

Current

Carlos Fernandez Valdivielso

Managing Director

Current

Name

Jose Maria Aracama Yoldi

Jose Maria Roig

Maria Puy Echarri Ventura

Carlos Fernandez Valdivielso

Work History

Title

Chief Executive Officer

President

Managing Director

Managing Director

Status

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.